The upcoming 10k will be for the year ending 6/30/19. The
The upcoming 10k will be for the year ending 6/30/19. The 10k will most likely only cover financial information including cash flow and Outstanding Share count as of 6/30/19 and not an up to the minute financial status. The Alfasigma partnership was inked 7/18/19 after this period. IPIX has stated that they are in the process of multiple partnering discussions so I would expect that Leo is not going to weaken his negotiating position by broadcasting confidential financial details beyond what has already been PRed. I personally do not expect more details on this until the next 8k in November. Monday’s PR discussing the upcoming B-IBD pill trial was outstanding news and IMO would not have been communicated if funding for the trial had not already been identified. This PR continues to solidify my belief that Leo is wisely managing IPIX funds while continuing to advance the science. This is also an example that additional new partnership and trial advancement news can come out at any time.
12
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
SmartFinancial Announces Upcoming Earnings Release SmartFinancial, Inc. (NYSE: SMBK) has revealed important details regarding its Fourth Quarter earnings for the year 2024. This is an exciting time for investors and stakeholders as the company prepares to share insights into its financial performance. Earnings Release Date and Conference Call Information The earnings...
Continue Reading
IntouchCX Strengthens Trust and Safety Solutions Through Acquisition IntouchCX has recently made headlines with its acquisition of WebPurify, a leading provider of innovative content moderation solutions that harness the power of artificial intelligence. This strategic move represents a significant advancement in IntouchCX's mission to redefine Trust and Safety solutions,...
Continue Reading
Y-mAbs Therapeutics Engages Investors at Upcoming Conferences This September, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a key player in the biopharmaceutical industry, is poised to attract investor interest. The company is known for its innovative radioimmunotherapy and antibody-based treatments designed to transform cancer care. Michael Rossi, the energetic CEO of...
Continue Reading
Overview of CorVel's Financial Performance CorVel Corporation (NASDAQ: CRVL) recently unveiled impressive results for the quarter and fiscal year, showcasing strong revenue gains and enhanced earnings metrics. The quarterly revenue hit $232 million, a notable rise from $207 million compared to the same quarter last year. This upward trend is mirrored across the fiscal...
Continue Reading
IQAX eBL Interoperability Approval Highlights IQAX Limited has made significant strides in enhancing its electronic bill of lading (eBL) solution by receiving official approval from the International Group of P&I Clubs (IG P&I Clubs). This approval affirms the capabilities of IQAX eBL's interoperable addendum, empowering users to perform eBL transactions across different...
Continue Reading
